← SynDRA
PF-03814735
SynDRA canonical compound SYN0039361 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | AURKA | AURKB |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AURKA INHIBITOR
- Serine/threonine-protein kinase Aurora-A inhibitor
- AURKB INHIBITOR
- Serine/threonine-protein kinase Aurora-B inhibitor
- aurora kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PDXK
- PIP4K2A
- PIM2
- PIM1
- PHKG2
- PGRMC1
- PFKP
- PDGFRB
- PKMYT1
- PCYT1A
- PASK
- PAK4
- PAICS
- OPA1
- OLA1
- PIP4K2C
- PKN1
- ABL1
- PRKAR2A
- PRKCZ
- PRKCQ
- PRKCI
- PRKCD
- PRKCB
- PRKCA
- PRKAG2
- PKN2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- NUAK2
- NTRK1
- NQO2
- MAPK8
- MARK4
- MARK3
Cross-references
Synonyms
- PF 03814735
- PF-3814735
- PF03814735
- Kinome_1769
- MLS006010949
- CHEMBL1983111
- SB19308
- NCGC00389594-01
- KB-74441
- SMR004703046
- BCP0726000114
- J3.628.238J
- N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide
- N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
- 6V5T4O5758
- RefChem:172226
- DTXCID701509886
- Aurora Kinase Inhibitor PF-03814735
- UNII-6V5T4O5758
- C23H25F3N6O2
- RYYNGWLOYLRZLK-RBUKOAKNSA-N
- MFCD16659065
- Abecarnil Impurity 3
- orb3137125
- SCHEMBL13116638
- BDBM50466804
- EX-A14819
- HB1441
- NSC801015
- s2725
- AKOS024458364
- CS-0684
- EBC-291094
- NSC-801015
- SDCCGSBI-0654456.P001
- NCGC00346652-07
- NCGC00346652-09
- FP104134
Look up PF-03814735 in the interactive SynDRA portal →